PTGX
NASDAQ · Biotechnology
Protagonist Therapeutics Inc
$99.36
+0.51 (+0.52%)
Financial Highlights (FY 2026)
Revenue
46.55M
Net Income
-131,658,232
Gross Margin
—
Profit Margin
-282.8%
Rev Growth
+20.1%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | — | — | 46.5% | 46.5% |
| Operating Margin | -343.6% | -309.3% | -13.0% | -11.6% |
| Profit Margin | -282.8% | -268.7% | -12.4% | -11.7% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 46.55M | 38.77M | 743.95M | 710.87M |
| Gross Profit | — | — | 346.14M | 330.75M |
| Operating Income | -159,954,840 | -119,896,190 | -96,749,229 | -82,581,428 |
| Net Income | -131,658,232 | -98,686,107 | -91,860,800 | -83,114,287 |
| Gross Margin | — | — | 46.5% | 46.5% |
| Operating Margin | -343.6% | -309.3% | -13.0% | -11.6% |
| Profit Margin | -282.8% | -268.7% | -12.4% | -11.7% |
| Rev Growth | +20.1% | +20.1% | +6.6% | +19.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 1.44B | 1.56B |
| Total Equity | — | — | 3.62B | 3.50B |
| D/E Ratio | — | — | 0.40 | 0.45 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -158,643,281 | -125,519,377 | -161,541,358 | -154,655,879 |
| Free Cash Flow | — | — | -86,698,990 | -88,894,573 |